Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Inventiva stock

IVA.PA
FR0013233012
A2DLV9

Price

2.12
Today +/-
+0.01
Today %
+0.47 %

Inventiva stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Inventiva stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Inventiva stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Inventiva stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Inventiva's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Inventiva Stock Price History

DateInventiva Price
1/3/20252.12 undefined
1/2/20252.11 undefined
12/31/20242.18 undefined
12/30/20242.19 undefined
12/27/20242.18 undefined
12/24/20242.24 undefined
12/23/20242.25 undefined
12/20/20242.19 undefined
12/19/20242.24 undefined
12/18/20242.15 undefined
12/17/20242.10 undefined
12/16/20242.22 undefined
12/13/20242.30 undefined
12/12/20242.31 undefined
12/11/20242.37 undefined
12/10/20242.37 undefined
12/9/20242.41 undefined

Inventiva Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Inventiva, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Inventiva from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Inventiva’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Inventiva. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Inventiva’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Inventiva’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Inventiva’s growth potential.

Inventiva Revenue, EBIT and net profit per share

DateInventiva RevenueInventiva EBITInventiva Net Income
2029e233.29 M undefined132.44 M undefined-8.72 M undefined
2028e128.69 M undefined-2.75 M undefined-60.17 M undefined
2027e55.33 M undefined-94.98 M undefined-80.22 M undefined
2026e39.14 M undefined-107.01 M undefined-125.85 M undefined
2025e25.6 M undefined-104.81 M undefined-131.28 M undefined
2024e5.54 M undefined-115.57 M undefined-171.51 M undefined
202317.48 M undefined-102.67 M undefined-110.43 M undefined
202212.18 M undefined-56.86 M undefined-54.27 M undefined
20214.19 M undefined-51.16 M undefined-49.64 M undefined
2020372,000 undefined-29.7 M undefined-33.62 M undefined
20197 M undefined-30.31 M undefined-30.22 M undefined
20183.2 M undefined-29.86 M undefined-33.62 M undefined
20174.8 M undefined-22.19 M undefined-19.08 M undefined
20169.45 M undefined-12.05 M undefined-7.05 M undefined
20154.88 M undefined-14.88 M undefined-8.82 M undefined
20143.28 M undefined-13.47 M undefined-7.49 M undefined
20133.07 M undefined-12.47 M undefined-7.14 M undefined

Inventiva Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
33494360412175253955128233
--33.33125.00-55.56-25.00100.00--200.0041.67-70.59400.0056.0041.03132.7382.03
566.67566.67425.00188.89425.00566.67283.33-175.00141.67100.00340.0068.0043.5930.9113.287.30
000000047170000000
-7-7-8-7-19-33-30-33-49-54-110-171-131-125-80-60-8
--14.29-12.50171.4373.68-9.0910.0048.4810.20103.7055.45-23.39-4.58-36.00-25.00-86.67
10.0310.0310.0310.0315.5220.5423.5233.8739.1741.4545.35000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Inventiva Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Inventiva is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20132014201520162017201820192020202120222023
                     
13.5217.1422.624.8759.0556.6935.84105.6986.5586.7426.92
0.840.830.910.770.060.0100.05403.81
1.313.063.787.376.813.3412.1523.6317.1810.6712.39
530477480471.88473410387320392373417
000.857.760.841.180.53.317.458.64.66
16.221.5128.6241.2567.2271.6348.88133115.58106.3848.19
6.035.915.574.964.524.263.723.283.27.399.13
00000000000
000000013.477.599.340
22.212.382.071.811.541.230.940.770.570.54
00000000000
62.8943.5124.010.580.832.373.141.712.441.6711.71
70.9251.6331.967.617.158.188.0919.391418.9621.37
87.1273.1360.5848.8674.3779.8156.96152.39129.58125.3469.56
                     
0000164223268386409421521
000044.9977.4686.01139.67165.07173.89201.86
000016.74-16.09-44.89-28.84-76.61-128.83-234.41
59.01042.7735.72000-0-00-0
00000000000
59.01042.7735.7261.8961.641.39111.2188.8745.48-32.03
1.681.893.614.365.388.377.496.9214.619.3637.68
002.182.172.082.322.342.892.933.353.57
3.883.61.761.921.414.253.954.084.042.253.68
0010.2500000000
0.060.060.190.140.140.150.080.021.285.755.23
5.625.547.758.69.0115.0813.8713.9122.8530.750.16
0.10.050.50.360.220.07010.048.8428.6632.18
22.1615.719.093.010000000
0.230.340.471.163.243.061.73.761.4311.1619.25
22.4916.0910.064.543.463.131.713.810.2739.8351.44
28.1121.6317.8113.1412.4718.2215.5727.7133.1270.53101.59
87.1221.6360.5848.8674.3779.8156.96138.92121.9811669.56
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Inventiva provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Inventiva's financial health and stability.

Assets

Inventiva's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Inventiva must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Inventiva after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Inventiva's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2013201420152016201720182019202020212022
00-8-7-19-33-30-33-49-54
0011121101
000000004-1
-16-14304-30-264
00-9-9-3003-43
0000000000
00-1-3-30-3-8-7-3
-16-14-13-14-17-34-28-30-47-44
0000000000
18181817600-8-18
18181917600-8-19
0000000000
00000009028
000045328101258
0000453281112537
----------
0000000000
235234-2-2069-190
-16.01-14.79-14.95-15.09-17.43-34.76-28.54-30.88-48.16-45.49
0000000000

Inventiva stock margins

The Inventiva margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Inventiva. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Inventiva.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Inventiva's sales revenue. A higher gross margin percentage indicates that the Inventiva retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Inventiva's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Inventiva's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Inventiva's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Inventiva. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Inventiva's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Inventiva Margin History

Inventiva Gross marginInventiva Profit marginInventiva EBIT marginInventiva Profit margin
2029e146.28 %56.77 %-3.74 %
2028e146.28 %-2.14 %-46.75 %
2027e146.28 %-171.66 %-144.98 %
2026e146.28 %-273.39 %-321.54 %
2025e146.28 %-409.39 %-512.8 %
2024e146.28 %-2,084.55 %-3,093.57 %
2023146.28 %-587.43 %-631.84 %
2022146.28 %-466.84 %-445.64 %
2021178.35 %-1,219.89 %-1,183.48 %
20201,186.56 %-7,983.87 %-9,037.37 %
2019146.28 %-433.15 %-431.81 %
2018146.28 %-933.94 %-1,051.52 %
2017146.28 %-462.58 %-397.81 %
2016146.28 %-127.56 %-74.59 %
2015146.28 %-305.13 %-180.98 %
2014146.28 %-410.2 %-228.27 %
2013146.28 %-406.19 %-232.57 %

Inventiva Stock Sales Revenue, EBIT, Earnings per Share

The Inventiva earnings per share therefore indicates how much revenue Inventiva has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Inventiva earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Inventiva's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Inventiva’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Inventiva's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Inventiva Revenue, EBIT and net profit per share

DateInventiva Sales per ShareInventiva EBIT per shareInventiva Earnings per Share
2029e2.68 undefined0 undefined-0.1 undefined
2028e1.48 undefined0 undefined-0.69 undefined
2027e0.64 undefined0 undefined-0.92 undefined
2026e0.45 undefined0 undefined-1.45 undefined
2025e0.29 undefined0 undefined-1.51 undefined
2024e0.06 undefined0 undefined-1.97 undefined
20230.39 undefined-2.26 undefined-2.43 undefined
20220.29 undefined-1.37 undefined-1.31 undefined
20210.11 undefined-1.31 undefined-1.27 undefined
20200.01 undefined-0.88 undefined-0.99 undefined
20190.3 undefined-1.29 undefined-1.28 undefined
20180.16 undefined-1.45 undefined-1.64 undefined
20170.31 undefined-1.43 undefined-1.23 undefined
20160.94 undefined-1.2 undefined-0.7 undefined
20150.49 undefined-1.48 undefined-0.88 undefined
20140.33 undefined-1.34 undefined-0.75 undefined
20130.31 undefined-1.24 undefined-0.71 undefined

Inventiva business model

Inventiva SA is a biopharmaceutical company based in France that specializes in the development of novel therapies for various diseases. The company was founded in 2002 by Pierre Broqua and Frédéric Cren to develop innovative drugs based on research on the human genome. Inventiva's business model is to develop a pipeline of drug candidates and either sell them or bring them into partnerships with other companies. The company has built a broad portfolio of patents and license agreements that allow it to develop a variety of products. Inventiva's research and development focuses on three key areas: fibrosis, oncology, and autoimmune diseases. In these areas, the company has several product candidates in various stages of clinical development. Inventiva's products include Lanifibranor, a drug for the treatment of fatty liver disease, which is currently in Phase III trials. Additionally, the company has several compounds in its oncology pipeline, including IVA337, IVA336, and IVA339, all of which have shown promising results in preclinical studies. In the field of autoimmune diseases, Inventiva is working on a compound called ABBV-157, which is being developed in collaboration with Abbvie. This compound is intended to help reduce inflammation in patients with rheumatoid arthritis and psoriasis. Overall, Inventiva has made significant progress in recent years and has achieved important milestones in the development of its products. The company has also entered into several partnerships with major pharmaceutical and biotech companies to bring its products to market. In 2020, Inventiva took the next important step in its growth strategy by announcing a merger with American company AbbVie. The acquisition is expected to accelerate the development and commercialization of Inventiva's products and provide the company with a strong partner in the international market. However, Inventiva has not limited itself to drug development. The company has also developed a range of services to support other companies in the development of new drugs. These include laboratory services, protein purification and analysis, cell culture, and more, offered through their own contract research organization (CRO) unit. In summary, Inventiva is an emerging company with a strong portfolio of products and services. The company has done excellent work in developing new medical technologies in recent years and is likely to have even more success in the future with the acquisition by AbbVie. Inventiva is one of the most popular companies on Eulerpool.com.

Inventiva SWOT Analysis

Strengths

Inventiva SA possesses several key strengths that contribute to its competitiveness in the market:

  • Strong and experienced management team with a successful track record.
  • Robust portfolio of intellectual property rights and patents.
  • Solid financial position and stable revenue streams.
  • Strategic partnerships with leading industry players.
  • Excellent R&D capabilities and innovative product pipeline.

Despite its strengths, Inventiva SA also faces certain weaknesses that may hamper its performance:

  • Limited market presence and brand recognition compared to larger competitors.
  • Reliance on a relatively small customer base, which increases vulnerability to economic fluctuations.
  • Overdependence on a specific technology or product line.

Inventiva SA can leverage the following opportunities to further grow and expand its business:

  • Emerging markets offer untapped potential for market penetration and increased sales.
  • Growing demand for innovative solutions in the target industry.
  • Strategic alliances and collaborations to access new markets and expand product offerings.
  • Advancements in technology that align with Inventiva SA's expertise and capabilities.

Inventiva SA faces several external threats that impede its growth and profitability:

  • Intense competition from established players with greater resources and market presence.
  • Economic downturns or fluctuations affecting consumer purchasing power.
  • Regulatory and legal challenges in intellectual property protection.
  • Disruptive technologies that may render current products or services obsolete.

Weaknesses

Despite its strengths, Inventiva SA also faces certain weaknesses that may hamper its performance:

  • Limited market presence and brand recognition compared to larger competitors.
  • Reliance on a relatively small customer base, which increases vulnerability to economic fluctuations.
  • Overdependence on a specific technology or product line.

Inventiva SA can leverage the following opportunities to further grow and expand its business:

  • Emerging markets offer untapped potential for market penetration and increased sales.
  • Growing demand for innovative solutions in the target industry.
  • Strategic alliances and collaborations to access new markets and expand product offerings.
  • Advancements in technology that align with Inventiva SA's expertise and capabilities.

Inventiva SA faces several external threats that impede its growth and profitability:

  • Intense competition from established players with greater resources and market presence.
  • Economic downturns or fluctuations affecting consumer purchasing power.
  • Regulatory and legal challenges in intellectual property protection.
  • Disruptive technologies that may render current products or services obsolete.

Opportunities

Inventiva SA can leverage the following opportunities to further grow and expand its business:

  • Emerging markets offer untapped potential for market penetration and increased sales.
  • Growing demand for innovative solutions in the target industry.
  • Strategic alliances and collaborations to access new markets and expand product offerings.
  • Advancements in technology that align with Inventiva SA's expertise and capabilities.

Inventiva SA faces several external threats that impede its growth and profitability:

  • Intense competition from established players with greater resources and market presence.
  • Economic downturns or fluctuations affecting consumer purchasing power.
  • Regulatory and legal challenges in intellectual property protection.
  • Disruptive technologies that may render current products or services obsolete.

Threats

Inventiva SA faces several external threats that impede its growth and profitability:

  • Intense competition from established players with greater resources and market presence.
  • Economic downturns or fluctuations affecting consumer purchasing power.
  • Regulatory and legal challenges in intellectual property protection.
  • Disruptive technologies that may render current products or services obsolete.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Inventiva Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Inventiva historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Inventiva shares outstanding

The number of shares was Inventiva in 2024 — This indicates how many shares 45.352 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Inventiva earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Inventiva's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Inventiva’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Inventiva's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Inventiva.

Inventiva shareholders

%
Name
Stocks
Change
Date
9.02556 % BVF Partners L.P.7,859,459010/17/2024
8.99849 % New Enterprise Associates (NEA)7,835,8842,262,93110/17/2024
8.24850 % The Invus Group, LLC7,182,7927,182,79210/17/2024
6.44491 % Cren (Frederic)5,612,224010/17/2024
5.92241 % Qatar Investment Authority5,157,23302/29/2024
5.82254 % Sofinnova Partners5,070,26602/29/2024
5.75175 % Andera Partners S.A.S.5,008,6205,008,62010/17/2024
5.19736 % Perceptive Advisors LLC4,525,8624,525,86210/17/2024
4.45854 % Broqua (Pierre)3,882,500010/17/2024
4.41626 % Yiheng Capital Management, L.P.3,845,6761,489,1762/29/2024
1
2

Inventiva Executives and Management Board

Mr. Frederic Cren

Inventiva Chairman of the Board, Chief Executive Officer, Co-Founder, Member of the Executive Committee
Compensation 387,696

Dr. Pierre Broqua

Inventiva Deputy Chief Executive Officer, Co-Founder, Chief Scientific Officer, Member of the Executive Committee (since 2018)
Compensation 294,108

Mr. Chris Buyse

(56)
Inventiva Independent Director, Representative of Pienter-Jan BVBA
Compensation 61,200

Dr. Annick Schwebig

(72)
Inventiva Independent Director, Representative of CELL+
Compensation 61,200

Mr. Heinz Maeusli

(60)
Inventiva Independent Director
Compensation 49,200
1
2
3

Inventiva Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
AbbVie Stock
AbbVie
SupplierCustomer-0,220,41-0,29-0,85-0,72-0,27
1

Most common questions regarding Inventiva

What values and corporate philosophy does Inventiva represent?

Inventiva SA represents values of innovation, research, and commitment to improving patients' lives. With a strong corporate philosophy, the company focuses on developing breakthrough therapies for the treatment of fibrotic diseases, oncology, and NASH. Inventiva SA's dedication to scientific excellence and collaborative partnerships drives its mission to address unmet medical needs and provide effective therapeutic solutions. Through its innovative approach and commitment to patient health, Inventiva SA has positioned itself as a leading player in the pharmaceutical industry.

In which countries and regions is Inventiva primarily present?

Inventiva SA is primarily present in France and Switzerland.

What significant milestones has the company Inventiva achieved?

Inventiva SA, a leading company in the stock market, has accomplished several significant milestones. One of its notable achievements includes the successful completion of Phase 2b clinical trials for its drug candidate, lanifibranor. Additionally, Inventiva SA has successfully secured partnerships and collaborations with various pharmaceutical companies to further advance its innovative research and development. The company's commitment to building a strong and diverse portfolio has also resulted in obtaining key patents and regulatory approvals for its ground-breaking therapies. These remarkable achievements highlight Inventiva SA's dedication to revolutionizing the healthcare industry and position the company as a promising investment opportunity.

What is the history and background of the company Inventiva?

Inventiva SA is a pharmaceutical company founded in 2011 in France. The company specializes in the development and commercialization of innovative therapies for the treatment of diseases with high unmet medical needs. With a strong expertise in drug discovery and medicinal chemistry, Inventiva aims to address significant therapeutic challenges through its proprietary technology platforms. The company has a diverse portfolio of drug candidates targeting a range of conditions, including fibrosis, oncology, and rare genetic diseases. Inventiva has established collaborations with various research and academic institutions to support its research efforts. With a dedicated team and promising pipeline, Inventiva SA is poised to make a significant contribution to the healthcare industry.

Who are the main competitors of Inventiva in the market?

The main competitors of Inventiva SA in the market include other companies operating in the biopharmaceutical industry, such as Novartis, Amgen, Gilead Sciences, and Pfizer. These companies also focus on research, development, and commercialization of innovative therapies for various diseases.

In which industries is Inventiva primarily active?

Inventiva SA is primarily active in the biopharmaceutical industry.

What is the business model of Inventiva?

The business model of Inventiva SA focuses on the development and commercialization of innovative therapies for the treatment of various diseases. As a biopharmaceutical company, Inventiva SA aims to discover and develop small molecule drugs that target various nuclear receptors involved in the regulation of gene expression. By leveraging its expertise in nuclear receptors, Inventiva SA aims to bring novel therapies to market that can address unmet medical needs. With a strong pipeline of drug candidates in various stages of development, Inventiva SA is dedicated to improving patients' lives and creating value for its shareholders through the research and development of innovative therapies.

What is the P/E ratio of Inventiva 2025?

The Inventiva P/E ratio is -0.73.

What is the P/S ratio of Inventiva 2025?

The Inventiva P/S ratio is 3.76.

What is the Quality Investing of Inventiva?

The Quality Investing for Inventiva is 7/10.

What is the revenue of Inventiva 2025?

The expected Inventiva revenue is 25.6 M EUR.

How high is the profit of Inventiva 2025?

The expected Inventiva profit is -131.28 M EUR.

What is the business model of Inventiva

The company Inventiva SA is a company specializing in the development of therapies for serious diseases. The company is based in France and also has branches in Germany and the USA. The various divisions of Inventiva SA include drug development and clinical research, as well as the manufacturing of diagnostics and medications. The company specializes in the development of medications for serious diseases such as rare genetic disorders or fibrosis. It takes an interdisciplinary approach and works closely with research institutions and biopharmaceutical companies. One of Inventiva SA's key products is the medication Lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a liver disease caused by obesity and diabetes, which can lead to cirrhosis and liver cancer. Lanifibranor is intended to improve liver health and reduce inflammation by influencing various signaling pathways in the body. The medication is currently in clinical development and has already shown promising results in clinical trials. Another product of Inventiva SA is the diagnostic test called Odiparcil, which supports the treatment of mucopolysaccharidosis (MPS). MPS is a rare genetic disease that can cause debilitating symptoms such as bone pain, shortness of breath, and changes in facial features. The Odiparcil test allows for the diagnosis of MPS and helps doctors choose the right therapy for their patients. Inventiva SA mainly finances its research and development projects through partnerships and licensing agreements with major pharmaceutical companies. For example, the company has a partnership with AbbVie, a global leader in biopharmaceuticals, to advance the development of Lanifibranor. Additionally, the company has significant investments from public and private investors as well as foundations. Overall, Inventiva SA takes a strategic and scientific approach to develop medications and diagnostics for serious diseases with unmet medical needs. The company has a strong pipeline of products in development and a promising partnership with a global biopharmaceutical manufacturer. With its focus on developing innovative therapies for complex diseases, Inventiva SA can contribute to improving the lives of millions of patients worldwide.

What is the Inventiva dividend?

Inventiva pays a dividend of 0 EUR distributed over payouts per year.

How often does Inventiva pay dividends?

The dividend cannot currently be calculated for Inventiva or the company does not pay out a dividend.

What is the Inventiva ISIN?

The ISIN of Inventiva is FR0013233012.

What is the Inventiva WKN?

The WKN of Inventiva is A2DLV9.

What is the Inventiva ticker?

The ticker of Inventiva is IVA.PA.

How much dividend does Inventiva pay?

Over the past 12 months, Inventiva paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inventiva is expected to pay a dividend of 0 EUR.

What is the dividend yield of Inventiva?

The current dividend yield of Inventiva is .

When does Inventiva pay dividends?

Inventiva pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Inventiva?

Inventiva paid dividends every year for the past 0 years.

What is the dividend of Inventiva?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Inventiva located?

Inventiva is assigned to the 'Health' sector.

Wann musste ich die Aktien von Inventiva kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Inventiva from 1/5/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 1/5/2025.

When did Inventiva pay the last dividend?

The last dividend was paid out on 1/5/2025.

What was the dividend of Inventiva in the year 2024?

In the year 2024, Inventiva distributed 0 EUR as dividends.

In which currency does Inventiva pay out the dividend?

The dividends of Inventiva are distributed in EUR.

All fundamentals about Inventiva

Our stock analysis for Inventiva Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inventiva Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.